Analysis of Hepatotoxicity Associated With TKIs in Solid Tumors

home / insights / analysis-of-hepatotoxicity-associated-with-tkis-in-solid-tumors

Tanios S. Bekaii-Saab, MD, analyzes the common adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs) across solid tumors, with a special focus on hepatotoxicity and the clinical implications of this AE for future clinical studies of TKIs in combination with immune checkpoint inhibitors.